Previous 10 | Next 10 |
Bellicum Pharmaceuticals (NASDAQ: BLCM ): Q4 GAAP EPS of -$5.82 misses by $1.49 . Revenue of $5.13M vs. $0.31M in 4Q18. Press Release More news on: Bellicum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK ™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson HOUSTON, March 12, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NA...
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options. The Comp...
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the Company effected a reverse stock spli...
HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approv...
NeuroMetrix (NASDAQ: NURO ) -33% on Q4 results . More news on: NeuroMetrix, Inc., NIO Limited, Genprex, Inc., Stocks on the move, , Read more ...
Gainers: Allied Healthcare Products (NASDAQ: AHPI ) +115% . More news on: Allied Healthcare Products, Inc., NanoViricides, Inc., Vaccinex, Inc., Stocks on the move, , Read more ...
Camber Energy (NYSEMKT: CEI ) +36% on announcing letter of intent regarding Camber’s proposed acquisition of Viking. More news on: Camber Energy, Inc., Tonix Pharmaceuticals Holding Corp., eHealth, Inc., Stocks on the move, Read more ...
Bellicum Pharmaceuticals (NASDAQ: BLCM ) perks up 9% premarket on light volume on the heels of Phase 1 translational data on lead GoCAR-T candidate BPX-601 in patients with advanced pancreatic cancer. The results were presented at the ASCO GI Cancers Symposium in San Francisco....
HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational results for BPX-601 at the American Society of Clinical Oncology Gastrointestin...
News, Short Squeeze, Breakout and More Instantly...
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...